In simple terms, what question is this study trying to answer?
This pilot study is asking whether new generation GLP-1 based highly effective anti-obesity medications (HEAOMs, semaglutide and tirzepatide) cause early changes in bone health during the first year of treatment, when weight loss tends to be most rapid. This study focuses on whether these medications affect bone quality and strength in ways that may not be detected by standard bone density testing alone. We are studying these effects in older men and postmenopausal women who are most at-risk for compromised bone health.
Why does this study matter? What could it mean for people?
HEAOMs are changing obesity treatment and are now being used by millions of people because of their substantial benefits for weight loss and metabolic health. At the same time, we know from prior research that rapid weight loss from dieting or bariatric surgery can increase bone turnover, reduce bone density, and potentially raise fracture risk. This study matters because we need to understand whether similar skeletal changes occur with HEAOM-associated weight loss so clinicians can help people lose weight safely while protecting long-term bone and musculoskeletal health.
What motivated you to explore the relationship between anti obesity medications and bone health?
HEAOMs are producing unprecedented levels of weight loss and are rapidly changing the obesity treatment landscape. Even modest weight loss has been linked to skeletal changes. These new generation HEAOMs are inducing significant levels of weight loss in some people – approaching what is observed in bariatric surgery. While these medications have been studied extensively for effects on diabetes, cardiovascular disease, sleep apnea, and body weight, far less is known about their impact on the skeleton.
Why are bone microarchitecture and bone turnover important to study in people using highly effective anti obesity medications, especially beyond standard bone density tests?
Standard bone density scans, such as DXA, provide useful information about bone mineral density, but they cannot fully capture bone quality or internal bone structure. Bone strength depends not only on density, but also on how bone is organized microscopically. Bone microarchitecture refers to the structure of cortical and trabecular bone, while bone turnover reflects how actively bone is being broken down and rebuilt. These measures may change earlier than bone density itself. By studying microarchitecture and turnover together, we hope to gain a more sensitive and complete understanding of how rapid medication-induced weight loss affects skeletal health.
What does existing research tell us about weight loss and bone health, and what key gaps does this study aim to address, particularly related to GLP 1 receptor agonists?s Here
Research from lifestyle-based weight loss and bariatric surgery consistently shows that weight loss can increase bone turnover and contribute to bone loss, especially in older adults and postmenopausal women. However, much less is known about the skeletal effects of new generation HEAOMs. Some studies suggest these medications may have neutral or even favorable effects on bone in animal models, while emerging human data raise concerns about declining bone density and higher fracture risk. Most previous human studies have relied primarily on standard DXA scans and have not evaluated detailed bone microarchitecture or strength. This study is designed to address those gaps using advanced imaging and biochemical markers collected during the period of most rapid weight loss.
What is HR pQCT, and why was it the right tool to use for this pilot study? What makes this approach different from prior research in this area?
HR-pQCT, or high-resolution peripheral quantitative computed tomography, is an advanced imaging technique that provides three-dimensional, high-resolution images of bone structure. Unlike standard DXA scans, HR-pQCT can separately evaluate cortical and trabecular bone, measure volumetric bone density, and estimate bone strength through finite element analysis. In this study, we are using HR-pQCT scans of the distal radius and distal tibia to detect subtle skeletal changes that may occur early during treatment. This approach is different from much of the existing literature because it moves beyond bone density alone and combines advanced imaging with fasting biochemical markers of bone turnover, body composition, dietary intake, physical activity, and sleep data collected longitudinally.
What early changes in bone microarchitecture or turnover are you hoping to observe during this pilot phase?
As an exploratory pilot study, we are approaching the project with scientific curiosity rather than defined outcomes. We want to know if the loss of bone is proportional to weight loss with these new generation medications. Thus, this pilot study will focus on quantifying early changes in bone microarchitecture, bone strength, and bone turnover. We will also examine whether changes in body composition, lean mass, dietary protein intake, physical activity, and sleep patterns influence these skeletal responses.
How might findings from this study inform future clinical care, wellness guidance, or long term considerations for people?
If we identify early skeletal changes during treatment, the findings could help shape future recommendations around bone health monitoring and prevention strategies for people using these medications. For example, clinicians may eventually incorporate more individualized guidance related to resistance exercise, adequate protein intake, calcium and vitamin D optimization, or bone health screening in higher-risk populations such as postmenopausal women and older adults. The goal is not to discourage treatment, but to enhance health span.
If the results are promising, what are the next steps for this line of research?s Here
This pilot study is designed to generate preliminary data that can support larger and more definitive longitudinal studies. Future work could involve larger sample sizes, longer follow-up, and mechanistic studies examining how changes in lean mass, nutrition, physical activity, and sleep influence skeletal outcomes during anti-obesity medication treatment. We are also interested in developing and testing lifestyle interventions that may help preserve bone health during weight loss, particularly exercise and nutrition strategies targeted toward maintaining muscle and skeletal strength.
What else should people know about this study
One important aspect of this study is that it focuses on people at potentially higher risk for bone loss—specifically postmenopausal women and men age 50 and older. The study is embedded within a broader observational trial that also tracks body composition, physical activity, sleep, diet quality, and cardiometabolic health over time in individuals of all ages initiating HEAOMs.
-1.png)
